Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study

BACKGROUND: Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Żok, Jolanta, Bieńkowski, Michał, Radecka, Barbara, Korniluk, Jan, Adamowicz, Krzysztof, Duchnowska, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112028/
https://www.ncbi.nlm.nih.gov/pubmed/33971834
http://dx.doi.org/10.1186/s12885-021-08183-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112028/
https://www.ncbi.nlm.nih.gov/pubmed/33971834
http://dx.doi.org/10.1186/s12885-021-08183-y

Ejemplares similares